Retinoblastoma is an aggressive malignant childhood retinal neoplasm. Protheragen advances diagnostic and therapeutic development solutions for retinoblastoma, covering hereditary, intraocular and metastatic disease subtypes.
Introduction to Retinoblastoma
Retinoblastoma is a highly malignant pediatric retinal neoplasm driven primarily by biallelic RB1 gene inactivation. It encompasses distinct clinical‑biological subtypes, including hereditary, intraocular, and metastatic forms, which differ in genetic background, lesion scope, prognosis and clinical‑management strategies.
- Hereditary Retinoblastoma: Hereditary retinoblastoma is driven by germline RB1 loss‑of‑function mutations, disrupting cell‑cycle regulation and triggering uncontrolled retinal cell proliferation. This autosomal‑dominant predisposition accounts for approximately 40 % of total cases; nearly all bilateral retinoblastoma falls within this category, presenting multifocal retinal lesions. Patients carry elevated risks for secondary malignancies, and germline variants can be transmitted to offspring, bringing severe threats to pediatric vision and long‑term survival.
- Intraocular Retinoblastoma: Intraocular retinoblastoma describes tumors confined entirely within the globe, without extra‑ocular spread. It includes both hereditary bilateral multifocal cases and sporadic unilateral non‑hereditary presentations. Clinical manifestations may include leukocoria, strabismus and intra‑ocular seeding; risk of vision loss depends on tumor size, location and vitreous/subretinal seeding status.
- Metastatic Retinoblastoma: Metastatic retinoblastoma represents advanced‑stage disease with tumor extension beyond the ocular globe. Malignant cells may invade the optic nerve, disseminate to central nervous system, bone marrow or distant organs, and carries significantly poorer prognosis. High‑risk histologic features from enucleated specimens trigger systemic metastatic‑workup surveillance.
Fig.1 Diagnosis and genomic profiles of bilateral retinoblastoma. (Wong E. Y.,
et al., 2021)
Genetic Diagnostics for Retinoblastoma
- RB1 Gene Mutation Analysis: Molecular diagnosis of bilateral RB relies on genetic testing for germline mutations in the RB1 gene. Carrier identification can be performed through blood and saliva samples.
- Preimplantation Genetic Diagnosis (PGD): In families with a history of retinoblastoma, preimplantation genetic diagnosis PGD may be used during in vitro fertilization to select embryos free of the RB1 mutation, thereby decreasing the likelihood of transmitting the disease to children.
Therapeutics Development for Retinoblastoma
- Ophthalmic Artery Chemotherapy (OAC)
Ocular (or ophthalmic) artery chemotherapy (OAC) has become a revolutionary therapeutic option for bilateral retinoblastoma. This technique consists of selective catheterization of the ophthalmic artery for the direct delivery of chemotherapy to the affected eye. With OAC, drug delivery is localized, which helps to achieve maximal control of the tumor and minimal systemic side effects.
- Intravitreous Chemotherapy
The process of intravitreous chemotherapy consists of injecting chemotherapy medications directly into the eye's vitreous body. This method is notably useful for vitreous seeds and has been effective in preventing recurrence. Reported response rates to melphalan and topotecan are high with minimal systemic side effects. Intravitreal chemotherapy is usually combined with OAC for better results.
- Targeted Therapies
New studies are looking into biologically targeted therapies and immunotherapies directed at retinoblastoma cells. These new approaches look to take advantage of molecular weaknesses in the cancer cells while protecting the surrounding tissues. One example is the ongoing research into mTOR inhibitors as targeted therapies and the use of immune checkpoint inhibitors as immunotherapies to improve outcomes with fewer detrimental effects.
Our Services
Recognizing the distinctive implications of Bilateral Retinoblastoma, Protheragen has a customized service approach for every client. Our specialist teams offer fully integrated research assistance alongside tailored therapeutic and diagnostic services to guarantee that all elements of Retinoblastoma therapeutics development are skillfully managed.
- RB1 Mutation Mouse Models
- Human Y79 Cell Xenograft Mouse Models
- Intraocular Injection Rabbit Models
- Non-Human Primate Models
Protheragen's state-of-the-art facilities and expert team provide comprehensive preclinical testing, including in vitro and in vivo studies. We utilize advanced cell culture models and animal models to evaluate the efficacy and safety of new therapeutics. If you are interested in our services, please feel free to contact us.
References
- Wong, Elyssa Y., et al. "Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy." NPJ Precision Oncology 5.1 (2021): 73.
- Ancona-Lezama, David, Lauren A. Dalvin, and Carol L. Shields. "Modern treatment of retinoblastoma: A 2020 review." Indian journal of ophthalmology 68.11 (2020): 2356-2365.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
